CHEK1 and cancer: SRA737 (Sierra Oncology, Inc., San Mateo, California, USA) is a novel orally bioavailable selective Chk1 inhibitor that has shown single-agent preclinical activity in MYC-amplified models of neuroblastoma [5] and lymphoma [6] in addition to cancer cells with loss of B-family DNA polymerase function [7].